Celgene

NCT00038181

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

NCT00093223

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00045786

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

NCT00044382

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

NCT00044018

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

NCT00106613

A Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00106418

A Research Study for Patients With Prostate Cancer

NCT00065156

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

NCT00065351

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00093119

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

NCT00047281

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

NCT00096044

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00106301

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

NCT00093145

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00102687

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

NCT00106431

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

NCT00274443

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

NCT00179673

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00249002

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

NCT00274456

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

NCT00281528

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

NCT00394082

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

NCT00413036

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

NCT00394251

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

NCT00751296

Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

NCT00375193

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

NCT00388960

Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

NCT00461045

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT00463385

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

NCT00426764

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00812968

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

NCT00535873

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

NCT00538733

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT00540644

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

NCT00538824

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

NCT00744536

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

NCT00456846

First Line Therapy for Patients With Metastatic Breast Cancer

NCT00655668

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00717522

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

NCT00848328

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

NCT00747123

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

NCT00765102

Trial of Romidepsin and Bortezomib for Multiple Myeloma

NCT00843310

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

NCT00737529

"A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The EMERGE Trial"

NCT00840827

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00799513

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

NCT00875667

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT00946270

Pomalidomide for Myelofibrosis Patients

NCT00963105

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01076504

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

NCT01054144

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

NCT01074502

Apremilast in the Treatment of Moderate to Severe Acne

NCT01088373

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

NCT01121757

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

NCT01146574

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

NCT01718379

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

NCT01593410

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

NCT01159574

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01316523

Lenalidomide and Rituximab in Subjects with Previously Untreated Indolent Non-Hodgkin's Lymphoma

NCT01203943

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

NCT01237249

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

NCT01331824

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

NCT01350947

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

NCT01353664

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

NCT01364727

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

NCT01402284

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

NCT01472562

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

NCT01460940

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT01177735

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

NCT01466725

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

NCT01125176

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

NCT01565499

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

NCT01358734

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01599325

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

NCT01559129

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

NCT01566435

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

NCT02348528

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

NCT01617226

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

NCT01698801

A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

NCT01571635

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

NCT01666444

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01724177

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

NCT01730586

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

NCT01743859

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

NCT01647516

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01827111

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

NCT01702844

Single Arm on the Tolerability of Weekly Nab-paclitaxel

NCT01815242

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

NCT01836029

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01975610

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

NCT01928576

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01999582

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

NCT02017015

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

NCT03529175

Scheduling Nab-paclitaxel With Gemcitabine

NCT02045017

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

NCT02405364

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

NCT02033993

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

NCT02103062

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

NCT01946477

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT02124369

Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)

NCT02098473

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

NCT02185040

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

NCT02230917

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

NCT02192489

A Phase 2 Study With CC-220 in Skin Sarcoidosis

NCT02158702

Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

NCT02279394

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02328105

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

NCT02250326

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

NCT02269943

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

NCT03807999

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

NCT02374099

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02301143

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02289456

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

NCT02460276

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT02317991

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

NCT02232516

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02391662

Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

NCT02281084

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02047513

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

NCT02450877

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

NCT02523040

Lenalidomide for Adult Histiocyte Disorders

NCT02447666

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

NCT02531113

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02546986

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02392507

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

NCT02494258

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

NCT02538965

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT02601300

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02441686

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02654132

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

NCT02406222

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

NCT02685683

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

NCT02775903

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

NCT02718833

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02685059

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

NCT02807454

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

NCT02632305

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

NCT02897830

Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma

NCT02916771

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

NCT02900560

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02887248

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

NCT02767557

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

NCT02985190

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

NCT03049267

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis

NCT02977780

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02816021

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

NCT03069326

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

NCT03003520

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

NCT03000452

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT02942758

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

NCT03123016

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03059485

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

NCT03142191

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

NCT03054532

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

NCT03161483

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

NCT03140943

Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT03257631

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

NCT03118466

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

NCT03188172

MUK Nine b: OPTIMUM Treatment Protocol

NCT03241017

Durvalumab in DLBCL After Autologous Transplant

NCT03194542

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

NCT03030261

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

NCT03361748

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03345810

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

NCT03174275

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

NCT03331640

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

NCT03383575

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

NCT03342404

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03413800

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

NCT03493646

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

NCT03289299

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03376672

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

NCT03484702

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03392571

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients